BMS-986205 (Synonyms: BMS-986205; ONO-7701) |
Catalog No.GC19079
One-Click Copy Product Info
|
BMS-986205 is a selective, irreversible inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 of 1.1μM in HEK293 cells overexpressing human IDO1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1923833-60-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
BMS-986205 is a selective, irreversible inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 of 1.1μM in HEK293 cells overexpressing human IDO1[1, 2]. BMS-986205 possesses immunomodulatory and antitumor activities and has entered clinical trials for various cancer types, including bladder cancer, head and neck cancer, endometrial cancer, gastric cancer, melanoma, liver cancer, non-small cell lung cancer, and solid tumors[3, 4]. BMS-986205 can reverse the anti-autistic effects of Taprenepag by inhibiting IDO1[5]. BMS-986205 can inhibit the ubiquinone reduction site of respiratory chain complex I, thereby impairing mitochondrial ATP production and interfering with glycolysis and oxidative phosphorylation (OXPHOS)[6].
In vitro, treatment of Jurkat cells with BMS-986205 (0-100µM) for 72h induced cell death in a dose-dependent manner, with an IC50 value of 6.3μM[7].
In vivo, treatment of mice with unilateral ureteral obstruction (UUO) with BMS-986205 (10mg/kg) via intraperitoneal injection twice daily for 7 days reduced collagen deposition in the kidneys[8].
References:
[1] Cherney E C, Zhang L, Nara S, et al. Discovery and preclinical evaluation of BMS-986242, a potent, selective inhibitor of indoleamine-2, 3-dioxygenase 1[J]. ACS Medicinal Chemistry Letters, 2021, 12(2): 288-294.
[2] Wang X X, Sun S Y, Dong Q Q, et al. Recent advances in the discovery of indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors[J]. Medchemcomm, 2019, 10(10): 1740-1754.
[3] Safdarian A R, Farhangnia P, Rezaei N. Indoleamine 2, 3-dioxygenase (IDO) and cancerous cells[M]//Cancerous Cells: Immunobiology of Tumors and Metastasis. Cham: Springer Nature Switzerland, 2025: 475-497.
[4] Le Naour J, Galluzzi L, Zitvogel L, et al. Trial watch: IDO inhibitors in cancer therapy[J]. Oncoimmunology, 2020, 9(1): 1777625.
[5] Wang K, Zhang S, Wang Y, et al. Taprenepag restores maternal–fetal interface homeostasis for the treatment of neurodevelopmental disorders[J]. Journal of Neuroinflammation, 2024, 21(1): 307.
[6] Dreute J, Stengel J, Becher J, et al. Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes[J]. Cell Death & Differentiation, 2025: 1-18.
[7] Richards T, Brin E. Cell Based Functional Assays for IDO1 Inhibitor Screening and Characterization. Oncotarget, 9, 30814-30820[EB/OL].(2018)
[8] Jensen C G, Jensen M S, Tingskov S J, et al. Local inhibition of indoleamine 2, 3-dioxygenase mitigates renal fibrosis[J]. Biomedicines, 2021, 9(8): 856.
| Cell experiment [1]: | |
Cell lines | Jurkat cells |
Preparation Method | Jurkat cells were incubated with 0-100µM BMS-986205 for 72h. Cell viability was assessed using ATP Cell Viability Assay, and cell viability was expressed as a percentage of the untreated control group. |
Reaction Conditions | 0-100µM; 72h |
Applications | BMS-986205 treatment induced cell death with an IC50 of 6.3µM. |
| Animal experiment [2]: | |
Animal models | Male C57BL/6 mice |
Preparation Method | 22 mice were randomly divided into four experimental groups; Sham (n=5), Sham+10mg/mL BMS-986205 (n=5), 7dUUO (n=4), and 7dUUO+10mg/mL BMS-986205 (n=8). BMS-986205 (diluted in DMSO/Corn oil) was administered twice daily via intraperitoneal injection starting at the day of the surgery; control mice were injected with the corresponding solvent control. After seven days, the kidneys were extracted and blood was collected via cardiac puncture for further analysis. Biochemical analysis of blood samples was performed using a Roche Cobas 6000 analyzer and creatinine levels were determined using the Creatinine Assay Kit. |
Dosage form | 10mg/kg; 7 days; i.p. |
Applications | BMS-986205 treatment attenuates renal collagen deposition in UUO mice. |
References: | |
| Cas No. | 1923833-60-6 | SDF | |
| Synonyms | BMS-986205; ONO-7701 | ||
| Canonical SMILES | O=C(NC1=CC=C(Cl)C=C1)[C@H](C)[C@@](CC2)([H])CC[C@H]2C3=CC=NC4=C3C=C(F)C=C4 | ||
| Formula | C24H24ClFN2O | M.Wt | 410.91 |
| Solubility | DMSO : 50 mg/mL (121.68 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4336 mL | 12.1681 mL | 24.3362 mL |
| 5 mM | 486.7 μL | 2.4336 mL | 4.8672 mL |
| 10 mM | 243.4 μL | 1.2168 mL | 2.4336 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)